Elsevier

The Lancet

Volume 327, Issue 8484, 5 April 1986, Pages 765-767
The Lancet

AMPLIFICATION OF c-erbB-2 ONCOGENE IN HUMAN ADENOCARCINOMAS IN VIVO

https://doi.org/10.1016/S0140-6736(86)91782-4Get rights and content

Abstract

There are two genes related to the viral erbB gene in the human genome. c-erbB-1 is the same as the gene for the epithelial-growth-factor (EGF) receptor, and c-erbB-2 encodes a receptor-like protein very similar to, but distinct from, the EGF receptor. Hybridisation analysis of DNA from 101 fresh human malignant tumours showed that the c-erbB-2 gene was amplified in 5 of 63 adenocarcinomas and none of 38 other types of tumours, whereas the c-erbB-1/EGF-receptor gene was amplified only in 1 of 8 squamous-cell carcinomas. Thus, the protein products of the amplified c-erbB-2 gene may have a role in the evolution of adenocarcinomas, as does the EGF receptor in some squamous-cell carcinomas.

References (19)

There are more references available in the full text version of this article.

Cited by (357)

  • Pan-HER-targeted approach for cancer therapy: Mechanisms, recent advances and clinical prospect

    2018, Cancer Letters
    Citation Excerpt :

    The overexpression or amplification of HER2 has been observed in up to 30% of breast cancer patients and the HER2-positive subtype is significantly correlated with worse prognosis than HER2-negative breast cancer [20]. Numerous studies were performed to unveil the association between HER2 expression and survival outcome of other cancer types [21–23]. Moreover, many HER2-targeted drugs such as trastuzumab, have been developed or under clinical trials for cancer therapies, which we will describe more below.

  • Breast biomarker immunocytochemistry

    2018, The Breast: Comprehensive Management of Benign and Malignant Diseases
  • Erythro-austrobailignan-6 down-regulates HER2/EGFR/integrinβ3 expression via p38 activation in breast cancer

    2017, Phytomedicine
    Citation Excerpt :

    It is a member of the HER (or ErbB) growth factor receptor family. Amplification or overexpression of this oncogene is important in the development and progression of certain aggressive types of breast cancer occurring in 20–30% of breast cancer patients, classified as the HER2-positive subtype, with poor clinical outcomes (Boone et al., 2009; Fukushige et al., 1986; Harris et al., 2007; King et al., 1985; Semba et al., 1985; Slamon et al., 1987; Yokota et al., 1986). The HER2 expression can lead to impaired DNA repair, angiogenesis and metastasis (Boone et al., 2009; Kumar and Yarmand-Bagheri, 2001; Palmieri et al., 2007).

View all citing articles on Scopus
View full text